

Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A₁ receptor in DDT₁MF-2 cells

Alex J. Robinson, John M. Dickenson*

Department of Life Sciences, Faculty of Science and Mathematics, Nottingham Trent University, Clifton Lane, Nottingham NG11 8NS, UK

Received 17 November 2000; received in revised form 28 December 2000; accepted 12 January 2001

Abstract

The mitogen-activated protein kinase (MAPK) family consists of the p42/p44 MAPKs and the stress-activated protein kinases, c-Jun N-terminal kinase (JNK) and p38 MAPK. We have previously reported that the human adenosine A₁ receptor stimulates p42/p44 MAPK in transfected Chinese hamster ovary cells. In this study, we have investigated whether the endogenous adenosine A₁ receptor in the smooth muscle cell line, DDT₁MF-2 activates p42/p44 MAPK, JNK and p38 MAPK. The adenosine A₁ receptor agonist N⁶-cyclopentyladenosine stimulated time and concentration-dependent increases in p42/p44 MAPK and p38 MAPK phosphorylation in DDT₁MF-2 cells. No increases in JNK phosphorylation were observed following adenosine A₁ receptor activation. N⁶-cyclopentyladenosine-mediated increases in p42/p44 MAPK and p38 MAPK phosphorylation were blocked by the selective adenosine A₁ receptor antagonist 1,3-dipropylcyclopentylxanthine and following pretreatment of cells with pertussis toxin. Furthermore, adenosine A₁ receptor-mediated increases in p42/p44 MAPK were sensitive to the MAPK kinase 1 inhibitor PD 98059 (2'-amino-3'-methoxyflavone), whereas p38 MAPK responses were blocked by the p38 MAPK inhibitor SB 203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1*H*-imidazole). The broad range protein tyrosine kinase inhibitors genistein and tyrphostin A47 (α -cyano-(3,4-dihydroxy)thiocinnamide) did not block adenosine A₁ receptor stimulation of p42/p44 MAPK. For comparison, insulin-mediated increases in p42/p44 MAPK were blocked by genistein and tyrphostin A47. The Src tyrosine kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine) and the epidermal growth factor receptor tyrosine kinase inhibitor AG1478 (4-(3-chloroanilino)-6,7-dimethoxyquinazoline) also had no effect on adenosine A₁ receptor stimulation of p42/p44 MAPK. Furthermore, the protein kinase C inhibitors Ro 31-8220 (3-[1-[3-(2-isothioureido) propyl]indol-3-yl]-4-(1-methylindol-3-yl)-3-pyrrolin-2,5-dione), chelerythrine and GF 109203X (2-[1-(3-dimethylaminopropyl)-1*H*-indol-3-yl]-3-(1*H*-indol-3-yl)-maleimide) were without effect on adenosine A₁ receptor-induced p42/p44 MAPK phosphorylation. In contrast, wortmannin and LY 294002 (2-(4-morpholinyl)-8-phenyl-4*H*-1-benzopyran-4-one), inhibitors of phosphatidylinositol 3-kinase, attenuated adenosine A₁ receptor stimulation of p42/p44 MAPK phosphorylation. In conclusion, the adenosine A₁ receptor stimulates p42/p44 MAPK through a pathway which appears to be independent of tyrosine kinase activation but involves phosphatidylinositol 3-kinase. Finally, adenosine A₁ receptor stimulation in DDT₁MF-2 cells also activated p38 MAPK but not JNK via a pertussis toxin-sensitive pathway. © 2001 Elsevier Science B.V. All rights reserved.

Keywords: Adenosine A₁ receptor; MAP (mitogen-activated protein) kinase; DDT₁MF-2 cell

1. Introduction

Adenosine regulates a variety of physiological functions through the activation of specific cell surface receptors. To date, four adenosine receptors (A₁, A_{2A}, A_{2B} and A₃), belonging to the G-protein-coupled receptor superfamily, have been cloned and pharmacologically characterised (for extensive reviews see Olah and Stiles, 1995; Ralevic and

Burnstock, 1998). Adenosine A₁ receptors couple to pertussis toxin-sensitive G proteins (G_{i1}, G_{i2}, G_{i3}, and G_o) and regulate several intracellular signalling pathways including inhibition of adenylyl cyclase, opening of K⁺ channels and closing of voltage-sensitive Ca²⁺ channels (Olah and Stiles, 1995). Our previous studies have investigated adenosine A₁ receptor-mediated cell signalling pathways in the hamster vas deferens derived smooth muscle cell line, DDT₁MF-2. As expected, adenosine A₁ receptor stimulation in DDT₁MF-2 cells inhibits adenylyl cyclase activity as measured by the ability of adenosine A₁ receptor agonists to inhibit forskolin-stimulated cyclic AMP accumulation (Dickenson and Hill, 1993a). In addition, to

* Corresponding author. Tel.: +44-115-948-6683; fax: +44-115-948-6636.

E-mail address: john.dickenson@ntu.ac.uk (J.M. Dickenson).

the predicted negative coupling to adenylyl cyclase, adenosine A₁ receptor activation in DDT₁MF-2 also stimulates pertussis toxin-sensitive increases in inositol phosphate formation and Ca²⁺ mobilisation (measures of phospholipase C activation; White et al., 1992; Dickenson and Hill, 1993a). More recently, we have shown that the adenosine A₁ receptor also activates protein kinase B in DDT₁MF-2 cells suggesting that the adenosine A₁ receptor may also regulate anti-apoptotic cell signalling pathways (Germack and Dickenson, 2000). These observations clearly demonstrate the diversity of cell signalling pathways regulated by the adenosine A₁ receptor.

Mitogen-activated protein kinases (MAPKs) are a group of serine/threonine protein kinases comprising of three well characterised subfamilies: the p42/p44 extracellular regulated kinases (ERKs), also known as p42/p44 MAPKs; the c-Jun N-terminal kinases (JNKs) which are also known as stress-activated protein kinases and the p38 MAPKs (Denhardt, 1996; Widmann et al., 1999). The p42/p44 MAPKs are primarily associated with the regulation of cell proliferation and differentiation, whereas the JNKs and p38 MAPKs are involved in apoptosis, inflammation and responses to environmental stress (Paul et al., 1997; Ono and Han, 2000). The ERK pathway can be activated by receptor tyrosine kinases (e.g., growth factor receptors), whereas p38 MAPK and JNK are activated by stimuli such as UV irradiation, osmotic stress and inflammatory cytokines (Malarkey et al., 1995; Paul et al., 1997). Recent studies indicate that a wide range of G-protein-coupled receptors also activate the p42/p44 MAPK, p38 MAPK and JNK signalling pathways (for reviews see Sugden and Clerk, 1997; Van Biesen et al., 1996).

Several recent reports have shown that members of the adenosine receptor family activate MAPK signalling pathways. For example, perfusion of isolated rat hearts with adenosine and stimulation of the adenosine A_{2B} receptor in human mast cells results in the activation of p42/p44 MAPK, p38 MAPK and JNK signalling pathways (Haq et al., 1998; Feoktistov et al., 1999). The adenosine A_{2A} receptor has also been shown to activate p42/p44 MAPK in primary human endothelial cells (Sexl et al., 1997; Seidel et al., 1999). We have previously shown that the human adenosine A₁ receptor activates p42/p44 MAPK in transfected Chinese hamster ovary (CHO) cells (Dickenson et al., 1998). In the present study, we have investigated whether the endogenous adenosine A₁ receptor regulates p42/p44 MAPK, p38 MAPK and JNK signalling pathways in DDT₁MF-2 cells.

2. Materials and methods

2.1. Cell culture

The hamster vas deferens smooth muscle cell line (DDT₁MF-2) was obtained from the European Collection

of Animal Cell Cultures (Porton Down, Salisbury, UK). DDT₁MF-2 cells were cultured in 75-cm² flasks in Dulbecco's modified Eagles medium (DMEM) supplemented with 2 mM L-glutamine and 10% (v/v) foetal calf serum. Cells were maintained at 37°C in a humidified 5% CO₂ atmosphere until confluency and subcultured (1:10 split ratio) using trypsin (0.05% w/v)/EDTA (0.02% w/v). Cells for determination of p42/p44 MAPK, p38 MAPK and JNK activation were grown in 6-well cluster dishes.

2.2. Western blot analysis

DDT₁MF-2 cells were grown in 6-well plate cluster dishes and when 80–90% confluent placed in DMEM medium containing 0.1% bovine serum albumin for 16 h. Serum-starved cells were then washed once with Hanks/HEPES buffer, pH 7.4, and incubated at 37°C for 30 min in 500 µl/well of the same medium, where appropriate kinase inhibitors were added during this incubation period. Agonists were subsequently added in 500 µl of medium and the incubation continued for 5 min (unless otherwise stated) at 37°C. Each incubation was terminated by aspiration of the medium and the addition of 300 µl of ice-cold lysis buffer [150 mM NaCl, 50 mM Tris/HCl, 5 mM EDTA, 1% (v/v) IGEPAL CA-630, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS (sodium dodecyl sulphate), 1 mM Na₃VO₄, 1 mM NaF, 1 mM benzamidine, 0.1 mM phenylmethylsulphonylfluoride, 10 µg/ml aprotinin and 5 µg/ml leupeptin]. Cells were then incubated on ice for 5 min, after which the cell lysates were removed and placed into Eppendorf microcentrifuge tubes and vortexed. Insoluble material was removed (and discarded) by centrifugation (5 min; 12,000 g) and 250 µl of the cell lysate removed and stored at –20°C until required. Protein determinations were made using the method of Lowry et al. (1951) using bovine serum albumin as the standard.

Aliquots of the cell lysate (20 µg protein) were separated by Sodium Dodecyl Sulphate/Polyacrylamide Gel Electrophoresis (SDS/PAGE; 10% acrylamide gel) using a Bio-Rad Mini-Protean II system (1 h at 200 V). Proteins were transferred to nitrocellulose membranes using a Bio-Rad Trans-Blot system (1 h at 100 V in 25 mM Tris, 192 mM glycine and 20% MeOH). Following transfer, the membranes were washed with phosphate buffered saline (PBS) and blocked for 1 h at room temperature with 5% (w/v) skimmed milk powder in PBS. Blots were then incubated overnight at 4°C with primary antibodies in 5% (w/v) skimmed milk powder dissolved in PBS/Tween 20 (0.5% by volume). Primary antibodies were removed and the blot extensively washed with PBS/Tween 20. Blots were then incubated for 2 h at room temperature with the secondary antibody (goat anti-rabbit/mouse antibody coupled to horseradish peroxidase) at 1:1000 dilution in 5% (w/v) skimmed milk powder dissolved in PBS/Tween 20. Following removal of the secondary antibody, blots

were extensively washed as above and developed using the Enhanced Chemiluminescence detection system (Amersham) and quantified using the programme QuantiScan (BioSoft).

2.3. Data analysis

Agonist $p[EC_{50}]$ values ($-\log EC_{50}$; concentration of drug producing 50% of the maximal response) were ob-




Fig. 1. Adenosine A_1 receptor stimulation of p42/p44 MAPK in DDT₁MF-2 cells. Cell lysates (20 μ g) were analysed for p42/p44 MAPK phosphorylation by Western blotting using a phospho-specific p42/p44 MAPK antibody. Representative Western blots for each experiment are shown in the upper panels. Time-course profiles for (A) CPA and (C) adenosine-induced p42/p44 MAPK phosphorylation in DDT₁MF-2 cells treated with vehicle (time 0), CPA (1 μ M) or adenosine (100 μ M) for the indicated periods of time. Concentration–response curves for (B) CPA and adenosine (D) in DDT₁MF-2 cells treated with vehicle (control) or the indicated concentrations of CPA and adenosine for 5 min. Combined results represent the mean \pm S.E.M. from four (A), six (B), six (C) and four (D) independent experiments.

tained by computer assisted curve fitting by use of the computer programme Prism (GraphPAD, CA, USA). Statistical significance was determined by Student's unpaired *t*-test ($P < 0.05$ was considered statistically significant). All data are presented as mean \pm S.E.M. The *n* in the text refers to the number of separate experiments. Antagonist dissociation constants (K_D) were estimated by a modification of the method of Lazareno and Roberts (1987). A concentration–response curve to an agonist was generated and a concentration (*C*) of the agonist under study chosen which gave a response greater than 50% of the maximal response. The concentration of antagonist (IC_{50}) required to reduce the response of this concentration (*C*) of N^6 -cyclopentyladenosine (CPA) by 50% was then determined. The agonist concentration–response curve was fitted to a logistic equation as described above and a concentration of the agonist identified (C^1) which yielded a response equivalent to 50% of that produced by concentration *C* (in the absence of antagonist). The apparent K_D was then determined from the following relationship: $C/C^1 = IC_{50}/K_D + 1$.

2.4. Materials

Aprotinin, bovine serum albumin, N^6 -cyclopentyladenosine, Dulbecco's modified Eagles medium, DPCPX (1,3-dipropylcyclopentylxanthine), foetal calf serum, insulin, IGEPAL CA-630 (octylphenoxy)polyethoxyethanol, leupeptin and pertussis toxin were obtained from Sigma (Poole, Dorset, UK). AG 1478 (4-(3-chloroanilino)-6,7-dimethoxyquinazoline), BAPTA/AM ([1,2-bis(*o*-amino-5-bromophenoxy)ethane-*N,N,N',N'*-tetraacetic acid tetra(acetyl-methyl) ester)], chelerythrine, daidzein, epidermal growth factor, genistein, GF 109203X (2-[1-(3-dimethylaminopropyl)-1*H*-indol-3-yl]-3-(1*H*-indol-3-yl)-maleimide), LY 294002 (2-(4-morpholinyl)-8-phenyl-4*H*-1-benzopyran-4-one), PD 98059 (2'-amino-3'-methoxyflavone), PP2 (4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine), Ro 31-8220 (3-{1-[3-(2-isothioureido) propyl]indol-3-yl}-4-(1-methylindol-3-yl)-3-pyrrolin-2,5-dione), SB 203580 (4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1*H*-imidazole) and tyrphostin A47 (α -cyano-(3,4-dihydroxy)thiocinnamide) were from Calbiochem (Nottingham, UK). Phospho-specific p42/p44 MAPK (Thr²⁰²/Tyr²⁰⁴) and p38 MAPK (Thr¹⁸⁰/Tyr¹⁸²) antibodies were purchased from Sigma. Phospho-specific JNK (Thr¹⁸³/Tyr¹⁸⁵) antibody was from Promega. All other chemicals were of analytical grade.

3. Results

3.1. Adenosine A_1 receptor-mediated phosphorylation of p42/p44 MAPK

The adenosine A_1 receptor selective agonist N^6 -cyclopentyladenosine (CPA; 1 μ M) produced a marked increase

in p42 and p44 MAPK phosphorylation with dominant phosphorylation of p42 MAPK in DDT₁MF-2 cells (Fig. 1A). Maximal phosphorylation was observed after 5 min and then slowly declined towards basal. The phosphorylation of p42/p44 MAPK by CPA was concentration-dependent, producing a $p[EC_{50}]$ value of 8.98 ± 0.24 ($n = 6$; Fig. 1B). Adenosine also produced time-dependent (Fig. 1C) and concentration-dependent (Fig. 1D) increases in p42/p44 MAPK phosphorylation ($p[EC_{50}] = 7.18 \pm 0.36$; $n = 4$) in DDT₁MF-2 cells. CPA-mediated increases in p42/p44 MAPK phosphorylation were antagonised by the selective adenosine A_1 receptor antagonist DPCPX (1,3-dipropylcyclopentylxanthine) yielding an apparent K_D




Fig. 2. Effect of the selective adenosine A_1 receptor antagonist DPCPX and pertussis toxin on CPA-induced p42/p44 MAPK phosphorylation. (A) DDT₁MF-2 cells were preincubated for 30 min with the indicated concentrations of the selective adenosine A_1 receptor antagonist DPCPX before stimulating with 1 μ M CPA for 5 min. A representative immunoblot showing inhibition by DPCPX is depicted in the upper panel. Combined results obtained from five independent experiments (mean \pm S.E.M.) are shown in the lower panel. Data are expressed as the percentage of the control response to 1 μ M CPA (100%). (B) Control cells and cells treated with pertussis toxin (100 ng/ml for 16 h) before stimulating with CPA (1 μ M) for 5 min. Similar results were obtained in at least four independent experiments.

value of 0.9 ± 0.2 nM ($n = 5$; Fig. 2A). The adenosine A_1 receptor couples to the pertussis toxin-sensitive family of G-proteins (G_{i1} , G_{i2} , G_{i3} , and G_o) (Ralevic and Burnstock, 1998). As expected, pretreatment with pertussis toxin (100 ng ml^{-1} for 16 h) completely abolished CPA-induced p42/p44 MAPK phosphorylation in DDT₁MF-2 cells (Fig. 2B). MAP kinase kinase 1 (MEK1) is responsible for the dual phosphorylation and activation of p42/p44 MAPK (Widmann et al., 1999). Pretreatment with the MEK1 inhibitor, PD 98059 (50 μ M; 30 min; Dudley et al., 1995) significantly reduced CPA-induced phosphorylation of p42/p44 MAPK in DDT₁MF-2 cells ($79 \pm 11\%$ inhibition; $n = 4$; $P < 0.05$; Fig. 3A). Recent studies indicate that tyrosine kinases are involved in the regulation of p42/p44 MAPKs by G_i/G_o -protein-coupled receptors (for review see Lopez-Illasaca, 1998). We have recently shown that the broad range tyrosine kinase inhibitor, genistein blocked human adenosine A_1 receptor-mediated p42/p44 MAPK activation in transfected CHO cells (Dickenson et al., 1998). In this study, we explored the involvement of tyrosine kinases using genistein, tyrphostin A47 and the Src-family tyrosine kinase inhibitor, PP2 (Hanke et al., 1996). The effects of these tyrosine kinase inhibitors on CPA-induced p42/p44 MAPK activation were compared with responses obtained by activating the insulin receptor (protein tyrosine kinase receptor). Representative immunoblots obtained with each inhibitor are shown in Fig. 3 and the results obtained are summarised in Table 1. These data indicate that adenosine A_1 receptor coupling to p42/p44 MAPK in DDT₁MF-2 cells is independent of tyrosine kinase activation. Recent studies have also

Table 1

Effect of tyrosine kinase inhibitors on adenosine A_1 receptor and insulin-mediated p42/p44 MAPK phosphorylation in DDT₁MF-2 cells

Treatment	CPA (% of control)	<i>n</i>	Insulin (% of control)	<i>n</i>
Genistein (100 μ M)	94 ± 12	4	4 ± 2^a	3
Daidzein (100 μ M)	98 ± 7	3	95 ± 9	3
Tyrphostin A47 (100 μ M)	103 ± 8	4	8 ± 6^a	4
PP2 (10 μ M)	95 ± 10	4	86 ± 9	4

Serum-starved DDT₁MF-2 cells were preincubated for 30 min with the various tyrosine kinase inhibitors before stimulating with CPA (1 μ M) or insulin (100 nM) for 5 min. Values are expressed as a percentage of the response obtained with 1 μ M CPA (100%) and 100 nM insulin (100%) in control cells (independent controls were used for each inhibitor). Control cells were pretreated for 30 min with vehicle (0.1% dimethyl sulphoxide). Values represent the mean \pm S.E.M. of n experiments.

^aSignificantly ($P < 0.05$, Student's *t*-test) different from control responses.

demonstrated that G-protein-coupled receptors can activate p42/p44 MAPK via transactivation (ligand-independent) of the epidermal growth factor receptor tyrosine kinase (Zwick et al., 1999). In this study, preincubation of cells with AG1478 (1 μ M; 30 min), an inhibitor specific for the epidermal growth factor receptor tyrosine kinase had no significant effect on CPA (1 μ M)-mediated p42/p44 MAPK phosphorylation. In contrast, epidermal growth factor (10 nM)-induced p42/p44 MAPK phosphorylation was completely inhibited ($10 \pm 8\%$ of control response;




Fig. 3. Effect of MAPK kinase inhibition and various tyrosine kinase inhibitors on adenosine A_1 receptor stimulation of p42/p44 MAPK in DDT₁MF-2 cells. Representative immunoblots showing the effects of pretreating DDT₁MF-2 cells for 30 min with (A) the MAPK kinase inhibitor PD 98059 (50 μ M), (B) the broad range tyrosine kinase inhibitor genistein (100 μ M), (C) daidzein (100 μ M) the inactive analogue of genistein, (D) the broad range tyrosine kinase inhibitor tyrphostin A47 (100 μ M), (E) the Src tyrosine kinase inhibitor PP2 (10 μ M) and (F) AG1478 (1 μ M) the EGF receptor tyrosine kinase inhibitor. Cells were stimulated with CPA (1 μ M), insulin (100 nM) or EGF (10 nM) for 5 min. Cell lysates (20 μ g) were resolved by SDS/PAGE and transferred to nitrocellulose before being probed with antisera specific for phosphorylated p42/p44 MAPK. Similar results were obtained in at least three independent experiments.

Table 2

Effect of protein kinase C inhibitors and protein kinase C down-regulation on adenosine A₁ receptor and phorbol ester-mediated p42/p44 MAPK phosphorylation in DDT₁MF-2 cells

Treatment	CPA (1 μ M) (% of control)	<i>n</i>	PMA (1 μ M) (% of control)	<i>n</i>
Ro 31-8220 (10 μ M)	99 \pm 8	8	30 \pm 5 ^a	5
GF 109203X (1 μ M)	107 \pm 8	6	25 \pm 9 ^a	4
Chelerythrine (10 μ M)	102 \pm 10	7	19 \pm 6 ^a	4
Down-regulation	90 \pm 4	5	20 \pm 6 ^a	4

Serum-starved DDT₁MF-2 cells were preincubated for 30 min with the various protein kinase C inhibitors before stimulating with CPA (1 μ M) or phorbol 12-myristate 13-acetate (PMA, 1 μ M) for 5 min. Protein kinase C down-regulation was achieved by preincubating DDT₁MF-2 cells for 36 h with phorbol 12-myristate 13-acetate (PMA, 1 μ M) before stimulating with CPA (1 μ M) or PMA (1 μ M) for 5 min. Values are expressed as a percentage of the response obtained with 1 μ M CPA (100%) and 1 μ M phorbol 12-myristate 13-acetate (100%) in control cells (independent controls were used for each inhibitor). Control cells were pretreated for 30 min with vehicle (0.1% dimethyl sulphoxide). Values represent the mean \pm S.E.M. of *n* experiments.

^aSignificantly ($P < 0.05$, Student's *t*-test) different from control responses.

n = 4; Fig. 3E) by AG1478 (1 μ M). These data suggest that epidermal growth factor receptor transactivation is not involved in adenosine A₁ receptor-mediated p42/p44 MAPK activation in DDT₁MF-2 cells.




Fig. 4. Role of protein kinase C in adenosine A₁ receptor stimulation of p42/p44 MAPK in DDT₁MF-2 cells. DDT₁MF-2 cells were pretreated for 30 min with the protein kinase C inhibitors Ro 31-8220 (10 μ M), GF 109203X (1 μ M) and chelerythrine (10 μ M) before stimulating with (A) 1 μ M CPA or (B) 1 μ M phorbol 12-myristate 13-acetate (PMA) for 5 min. (C) DDT₁MF-2 cells were preincubated for 36 h with phorbol 12-myristate 13-acetate (PMA, 1 μ M) before stimulating with CPA (1 μ M) or PMA (1 μ M) for 5 min. Cell lysates (20 μ g) were resolved by SDS/PAGE and transferred to nitrocellulose before being probed with antisera specific for phosphorylated p42/p44 MAPK. Similar results were obtained in at least four independent experiments.

3.2. Role of protein kinase C and Ca²⁺ in adenosine A₁ receptor-induced p42/p44 MAPK phosphorylation

Our previous studies have shown that the adenosine A₁ receptor stimulates phospholipase C in DDT₁MF-2 cells via pertussis toxin-sensitive G-proteins (White et al., 1992). Phospholipase C activation generates the second messengers inositol 1,4,5-trisphosphate and 1,2-diacylglycerol, which mobilise intracellular Ca²⁺ and activate certain protein kinase C isoforms, respectively (Berridge, 1993). Indeed, the adenosine A₁ receptor in DDT₁MF-2 cells stimulates intracellular Ca²⁺ release, Ca²⁺ influx and increases in protein kinase C activity (Dickenson and Hill,




Fig. 5. Role of phosphatidylinositol 3-kinase in adenosine A₁ receptor-mediated phosphorylation of p42/p44 MAPK in DDT₁MF-2 cells. DDT₁MF-2 cells were preincubated for 30 min with the indicated concentrations of the phosphatidylinositol 3-kinase inhibitors (A) wortmannin and (B) LY 294002 before stimulating with 1 μ M CPA for 5 min. Cell lysates (20 μ g) were resolved by SDS/PAGE and transferred to nitrocellulose before being probed with antisera specific for phosphorylated p42/p44 MAPK. Representative immunoblots for wortmannin (A) and LY 294002 (B) are shown in the upper panels. Combined results obtained from five independent experiments (mean \pm S.E.M.) are shown in the lower panels. Data are presented as the percentage of the control response to 1 μ M CPA (100%) in the absence of PI-3K inhibitor. *Significantly different ($P < 0.05$) from the control response to 1 μ M CPA.

1993b; Gerwins and Fredholm, 1995). In this study, we have examined the role of Ca^{2+} and protein kinase C in the regulation of p42/p44 MAPK by the adenosine A_1 receptor in DDT₁MF-2 cells. The role of Ca^{2+} influx was explored by measuring p42/p44 MAPK responses in the absence of extracellular Ca^{2+} (using nominally Ca^{2+} -free Hanks/HEPES buffer containing 0.1 mM EGTA). This procedure prevents adenosine A_1 receptor-mediated Ca^{2+} influx in DDT₁MF-2 cells (Dickenson and Hill, 1993b). Removal of extracellular Ca^{2+} had no significant effect on CPA (1 μM ; $98 \pm 9\%$ of control response; $n = 4$) induced p42/p44 MAPK phosphorylation. The potential role of Ca^{2+} derived from intracellular stores was investigated using the Ca^{2+} chelator BAPTA (cells were preincubated for 30 min with 50 μM BAPTA/AM) in the absence of extracellular Ca^{2+} . Loading cells with BAPTA in the absence of extracellular Ca^{2+} did not inhibit CPA ($94 \pm 12\%$ of control; $n = 4$)-induced p42/p44 MAPK phospho-

rylation. These observations demonstrate that p42/p44 MAPK activation by adenosine A_1 receptor is independent of Ca^{2+} elevation in DDT₁MF-2 cells.

The role of protein kinase C in the regulation of p42/p44 MAPK by the adenosine A_1 receptor was explored using selective inhibitors of protein kinase C, 10 μM Ro 31-8220 (Davis et al., 1989), 1 μM GF 109203X and (Matiny-Brown et al., 1993) and 10 μM chelerythrine (Herbert et al., 1990). As summarised in Table 2, protein kinase C inhibition had no significant effect on 1 μM CPA-induced p42/p44 MAPK phosphorylation in DDT₁MF-2 cells (representative blots are shown in Fig 4A). In contrast, increases in p42/p44 MAPK phosphorylation elicited by phorbol 12-myristate 13-acetate (1 μM) were sensitive to 10 μM Ro 31-8220, 1 μM GF 109203X 10 μM chelerythrine (summarised in Table 2 and shown in Fig. 4B). Finally, the potential involvement of protein kinase C was also determined following down-regulation




Fig. 6. Adenosine A_1 receptor stimulation of p38 MAPK in DDT₁MF-2 cells. DDT₁MF-2 cells were treated with 0.5 M sorbitol for the indicated periods of time. Cell lysates were resolved by SDS/PAGE and transferred to nitrocellulose before being probed with antisera specific for (A) phospho p38 MAPK and (B) phospho JNK. Stimulation of DDT₁MF-2 cells with CPA produced (C) time-dependent (using 1 μM CPA) and (D) concentration-dependent increases in p38 MAPK phosphorylation (5 min stimulation). Combined results obtained from four independent experiments (mean \pm S.E.M.) are shown in the lower panels.

of protein kinase C by pretreating DDT₁MF-2 cells with the protein kinase C activator phorbol 12-myristate 13-acetate (1 μ M; 36 h). As shown in Fig. 4C, the subsequent activation of p42/p44 MAPK by phorbol 12-myristate 13-acetate (1 μ M) was abolished; however, responses to CPA (1 μ M) were unaffected in protein kinase C down-regulated cells.

3.3. Effect of phosphatidylinositol 3-kinase inhibition on adenosine A₁ receptor-induced p42/p44 MAPK phosphorylation

Phosphatidylinositol 3-kinase has been implicated in G_i-protein-coupled receptor-induced activation of p42/p44 MAPK (Sugden and Clerk, 1997; Van Biesen et al., 1996). Indeed, we have previously reported that human adenosine A₁ receptor stimulation of p42/p44 MAPK in transfected CHO cells is sensitive to the phosphatidylinositol 3-kinase inhibitors wortmannin and LY 294002 (Dickenson et al., 1998). In this study, we have examined the role of phosphatidylinositol 3-kinase in the regulation of p42/p44 MAPK by the adenosine A₁ receptor in DDT₁MF-2 cells. As shown in Fig. 5, responses to CPA (1 μ M) were inhibited following pretreatment (30 min) of cells with wortmannin and LY 294002. For example, wortmannin (100 nM) and LY 294002 (100 μ M) inhibited CPA (1 μ M)-induced p42/p44 MAPK responses by $57 \pm 8\%$ ($n = 5$) and $55 \pm 11\%$ ($n = 5$), respectively. These observations clearly demonstrate that a phosphatidylinositol 3-kinase-dependent pathway is involved in adenosine A₁ receptor-mediated p42/p44 MAPK activation in DDT₁MF-2 cells.

3.4. Effect of adenosine A₁ receptor stimulation on SAPK/JNK and p38 MAPK phosphorylation

We initially determined whether osmotic stress stimulates p38 MAPK and JNK activation in DDT₁MF-2 cells. Sorbitol (0.5 M) treatment activated p38 MAPK (Fig. 6A) and the 46 and 54 kDa isoforms of JNK (Fig. 6B) in DDT₁MF-2 cells, although with different time-course profiles. Stimulation of DDT₁MF-2 cells with CPA produced time-dependent (peak activation occurring at 5 min; Fig. 6C) and concentration-dependent ($p[EC_{50}] = 8.1 \pm 0.3$; $n = 4$; Fig. 6D) increases in p38 MAPK phosphorylation. However, CPA (1 μ M) did not stimulate measurable increases in JNK phosphorylation in DDT₁MF-2 cells during time course experiments conducted up to 40 min (data not shown). CPA-mediated increases in p38 MAPK phosphorylation were antagonised by the selective adenosine A₁ receptor antagonist DPCPX yielding an apparent K_D value of 1.2 ± 0.1 nM ($n = 5$; Fig. 7A). These data indicate that CPA-stimulated increases in p38 MAPK phosphorylation are mediated through the adenosine A₁ receptor in DDT₁MF-2 cells. Finally, pretreatment of DDT₁MF-2 cells with the p38 MAPK inhibitor SB 203580 (20 μ M) and




Fig. 7. Effect of the selective adenosine A₁ receptor antagonist DPCPX, pertussis toxin and SB 203580 on CPA-induced p38 MAPK phosphorylation. (A) DDT₁MF-2 cells were preincubated for 30 min with the indicated concentrations of the selective adenosine A₁ receptor antagonist DPCPX before stimulating with 1 μ M CPA for 5 min. A representative immunoblot showing inhibition by DPCPX is depicted in the upper panel. Combined results obtained from five independent experiments (mean \pm S.E.M.) are shown in the lower panel. Data are expressed as the percentage of the control response to 1 μ M CPA (100%). (B) Control cells and cells treated with pertussis toxin (16 h, 100 ng/ml) before stimulating with CPA (1 μ M) for 5 min. (C) Cells were pretreated for 30 min with the p38 MAPK inhibitor SB 203580 (20 μ M) prior to stimulating with 1 μ M CPA for 5 min. Similar results were obtained in at least four independent experiments.

pertussis toxin (100 ng/ml for 16 h) inhibited 1 μ M CPA-induced p38 MAPK phosphorylation by $91 \pm 7\%$ ($n = 5$; Fig. 7B) and $95 \pm 7\%$ ($n = 4$; Fig. 7C), respectively.

4. Discussion

We have previously reported that the human adenosine A₁ receptor activates p42/p44 MAPK signalling in trans-

fects CHO cells (Dickenson et al., 1998). In this study, using DDT₁MF-2 smooth muscle cells, we have shown for the first time that an endogenously expressed adenosine A₁ receptor stimulates p42/p44 MAPK activation. The activation of p42/p44 MAPK by G_i/G_o-protein-coupled receptors involves G protein-derived $\beta\gamma$ subunits, genistein-sensitive c-Src-related protein tyrosine kinase(s) and phosphatidylinositol 3-kinase activation in a Ras-dependent manner (Koch et al., 1994; Hawes et al., 1995, 1996; Garnovskaya et al., 1996; Igishi and Gutkind, 1998). Indeed, our previous studies have shown that human adenosine A₁ receptor coupling to p42/p44 MAPK activation in transfected CHO cells is blocked by the tyrosine kinase inhibitor genistein and by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY 294002 (Dickenson et al., 1998). In this study, wortmannin and LY 294002 also blocked p42/p44 MAPK phosphorylation by the adenosine A₁ receptor in DDT₁MF-2 cells. However, it is notable that adenosine A₁ receptor-induced p42/p44 MAPK responses in DDT₁MF-2 cells are insensitive to the broad range protein tyrosine kinase inhibitors genistein and tyrphostin A47. In marked contrast, p42/p44 MAPK responses to insulin were sensitive to genistein and tyrphostin A47. In addition, p42/p44 MAPK responses mediated via the G_q-protein-coupled histamine H₁ receptor in DDT₁MF-2 cells are sensitive to genistein and tyrphostin A47 (Robinson and Dickenson, 2000; unpublished observations). These data suggest that adenosine A₁ receptor coupling to p42/p44 MAPK in DDT₁MF-2 cells may involve genistein and tyrphostin A47-insensitive tyrosine kinases or is independent of tyrosine kinase activation. Furthermore, adenosine A₁ receptor stimulation of p42/p44 MAPK was also insensitive to the selective Src tyrosine kinase inhibitor PP2 and the epidermal growth factor receptor tyrosine kinase inhibitor AG1478. These data would seem to eliminate a potential for the Src family tyrosine kinases and epidermal growth factor receptor transactivation. Genistein-insensitive p42/p44 MAPK activation has been observed with other G_i-protein-coupled receptors including 5-HT_{1A} receptors and dopamine D₃ receptors (Cowen et al., 1996; Cussac et al., 1999). Similarly, p42/p44 MAPK responses mediated via receptors coupled to G_s proteins (adenosine A_{2B} receptors) and G_q proteins (P2Y₂ purinoceptors) have also been shown to be insensitive to genistein (Gao et al., 1999). Recent studies have shown that Ras-dependent activation of p42/p44 MAPK can be inhibited by the GTP-binding protein Rap1 (Zwartkruis and Bos, 1999). Interestingly, Mochizuki et al. (1999) have proposed that G _{α i} subunits activate p42/p44 MAPK by membrane recruitment of a novel Rap1 GTPase-activating protein (GAP) called rap1GAPII. These authors also showed that activation of the G_i-coupled muscarinic m2 receptor promotes the translocation of rap1GAPII from the cytosol to the membrane and decreases the levels of GTP-bound Rap1 (Mochizuki et al., 1999). These observations raise the intriguing possibility

that p42/p44 MAPK activation by the adenosine A₁ receptor in DDT₁MF-2 cells involves Rap1 inactivation via G _{α i} rather than $\beta\gamma$ -subunits. Such a mechanism may explain why adenosine A₁ receptor coupling to p42/p44 MAPK in DDT₁MF-2 cells is tyrosine kinase-independent.

Recent studies suggest that G_q/G₁₁-protein-coupled receptors preferentially employ protein kinase C and/or Ca²⁺ signals to activate p42/p44 MAPK in a Raf-dependent but Ras-independent manner (Sugden and Clerk, 1997). Since the adenosine A₁ receptor activates phospholipase C in DDT₁MF-2 cells, we examined the role of protein kinase C and Ca²⁺ in the regulation of p42/p44 MAPK by the adenosine A₁ receptor. The data presented indicate that adenosine A₁ receptor-induced p42/p44 MAPK responses in DDT₁MF-2 cells are independent of Ca²⁺ influx and intracellular Ca²⁺ release.

There is also increasing evidence for a role of protein kinase C (which may also explain genistein insensitivity) in G_i-protein-coupled receptor-mediated p42/p44 MAPK activation. For example, Takeda et al. (1999) reported that lysophosphatidic acid activates MAPK through a Ras-independent pathway that involves phosphatidylinositol 3-kinase-dependent activation of atypical protein kinase C- ζ . Similarly, the dopamine D₃ receptor couples to p42/p44 MAPK activation via phosphatidylinositol 3-kinase and an atypical protein kinase C isoform (Cussac et al., 1999). It is notable that responses to lysophosphatidic acid and the dopamine D₃ receptor were sensitive to Ro 31-8820, which at high concentrations (> 1 μ M) blocks the activation of atypical protein kinase C isoforms and insensitive to Gö 6976, which inhibits conventional Ca²⁺-dependent protein kinase C α and β I isoforms (Martiny-Brown et al., 1993). In this study, the data obtained using a range of protein kinase C inhibitors (with a broad inhibition spectrum) indicate that adenosine A₁ receptor-mediated p42/p44 MAPK phosphorylation is independent of protein kinase C activation.

In this study, we have also explored the potential regulation of p38 MAPK and JNK signalling pathways by the adenosine A₁ receptor. The p38 MAPK and JNK signalling pathways are typically activated by stimuli such as UV irradiation, osmotic stress and inflammatory cytokines, although an increasing number of G-protein-coupled receptors have been shown to activate these pathways (Paul et al., 1997; Ono and Han, 2000). The data presented in this study clearly indicate that the adenosine A₁ receptor stimulates p38 MAPK phosphorylation through a pertussis toxin-sensitive pathway, indicating a role for G_i/G_o proteins. At present, the signalling pathways that connect G-protein-coupled receptors to p38 MAPK are largely unknown. Recent studies have shown that muscarinic m2 (G_i-coupled) and β -adrenoceptor (G_s-coupled) activation of p38 MAPK is mediated via G $\beta\gamma$, whereas activation by the G_q-coupled muscarinic m1 receptor involves G α _{q/11} and G $\beta\gamma$ (Yamauchi et al., 1997). The EC₅₀ for CPA-induced p38 MAPK activation (ca. 20 nM) is comparable to

values previously reported for adenosine A_1 receptor-mediated inositol phosphate accumulation (26 nM; White et al., 1992) and Ca^{2+} mobilisation (19 nM; Dickenson and Hill, 1993a) in DDT₁MF-2 cells. In contrast, the EC_{50} values for CPA-stimulated p42/p44 MAPK activation and inhibition of adenylyl cyclase in DDT₁MF-2 cells are 1.3 and 2.8 nM, respectively (this study, Dickenson and Hill, 1993a). Recent studies suggest that G_i -protein-coupled receptors, such as the adenosine A_1 receptor, mediate inhibition of adenylyl cyclase via $G\alpha_i$ subunits and stimulate phospholipase C via $G\beta\gamma$ subunits released from G_i proteins (Dickenson and Hill, 1998). The higher concentrations of CPA required to stimulate inositol phosphate accumulation and Ca^{2+} mobilisation compared to the inhibition of adenylyl cyclase may reflect signalling pathways involving $G\beta\gamma$ and $G\alpha_i$ subunits, respectively. Hence, the EC_{50} values for CPA-induced stimulation of p42/p44 MAPK and p38 MAPK suggest the involvement of $G\alpha_i$ and $G\beta\gamma$ -dependent pathways, respectively. However, further studies are required in order to identify the molecular mechanisms mediating p38 MAPK activation by the adenosine A_1 receptor and to determine whether p38 MAPK activation by the adenosine A_1 receptor contributes to the physiological effects of adenosine.

In summary, we have shown that the adenosine A_1 receptor stimulates p42/p44 MAPK and p38 MAPK in DDT₁MF-2 cells but not JNK. It is now apparent that the adenosine A_1 receptor in DDT₁MF-2 cells regulates a wide variety of signalling pathways including inhibition of adenylyl cyclase and activation of phospholipase C (with associated increases in intracellular Ca^{2+} and protein kinase C activity), p42/p44 MAPK, p38 MAPK and protein kinase B (Dickenson and Hill, 1993a; White et al., 1992; Gerwins and Fredholm, 1995; Germack and Dickenson, 2000). In addition, the adenosine A_1 receptor can potentiate inositol phosphate and calcium responses triggered by G_q -protein-coupled receptors in DDT₁MF-2 cells (Dickenson and Hill, 1993b; Hill et al., 1994). Future studies will investigate the possibility of intracellular cross-talk occurring between adenosine A_1 receptor and G_q -protein-coupled receptor signalling at the level of p42/p44 MAPK and p38 MAPK.

Acknowledgements

This work was funded by The Nottingham Trent University.

References

- Berridge, M.J., 1993. Inositol triphosphate and calcium signalling. *Nature* 361, 315–325.
- Cowen, D.S., Sowers, R.S., Manning, D.R., 1996. Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine(1A) receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis. *J. Biol. Chem.* 271, 22297–22300.
- Cussac, D., Newman-Tancredi, A., Pasteau, V., Millan, M.J., 1999. Human dopamine D_3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. *Mol. Pharmacol.* 56, 1025–1030.
- Davis, P.D., Hill, C.H., Keech, E., Lawton, G., Nixon, J.S., Sedgwick, A.D., Wadsworth, J., Westmacott, D., Wilkinson, S.E., 1989. Potent selective inhibitors of protein kinase C. *FEBS Lett.* 259, 61–63.
- Denhardt, D.T., 1996. Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. *Biochem. J.* 318, 729–747.
- Dickenson, J.M., Hill, S.J., 1993a. Adenosine A_1 receptor stimulated increases in intracellular calcium in the smooth muscle cell line, DDT₁MF-2. *Br. J. Pharmacol.* 108, 85–92.
- Dickenson, J.M., Hill, S.J., 1993b. Intracellular cross-talk between receptors coupled to phospholipase C via pertussis toxin-sensitive and insensitive G-proteins in DDT₁MF-2 cells. *Br. J. Pharmacol.* 109, 719–724.
- Dickenson, J.M., Hill, S.J., 1998. Involvement of G-protein $\beta\gamma$ subunits in coupling the adenosine A_1 receptor to phospholipase C in transfected CHO cells. *Eur. J. Pharmacol.* 355, 85–93.
- Dickenson, J.M., Blank, J.L., Hill, S.J., 1998. Human adenosine A_1 receptor and P2Y₂-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells. *Br. J. Pharmacol.* 124, 1491–1499.
- Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J., Saltiel, A.R., 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. *Proc. Natl. Acad. Sci. U. S. A.* 92, 7686–7689.
- Feoktistov, I., Goldstein, A.E., Biaggioni, I., 1999. Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase in adenosine A_{2B} receptor-mediated interleukin-8 production in human mast cells. *Mol. Pharmacol.* 55, 726–735.
- Gao, Z., Chen, T., Weber, M.J., Linden, J., 1999. A_{2B} adenosine and P2Y₂ receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. *J. Biol. Chem.* 274, 5972–5980.
- Garnovskaya, M.N., Van Biesen, T., Hawes, B.E., Ramos, S.C., Lefkowitz, R.J., Raymond, J.R., 1996. Ras-dependent activation of fibroblast mitogen-activated protein kinase by 5-HT_{1A} receptor via a G protein $\beta\gamma$ subunit initiated pathway. *Biochemistry* 35, 13716–13722.
- Germack, R., Dickenson, J.M., 2000. Activation of protein kinase B by the A_1 adenosine receptor in DDT₁MF-2 cells. *Br. J. Pharmacol.* 130, 867–874.
- Gerwins, P., Fredholm, B.B., 1995. Activation of adenosine A_1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 351, 186–193.
- Hanke, J.H., Gardner, J.P., Dow, R.L., Changelian, P.S., Brissette, W.H., Weringer, E.J., Pollok, B.A., Connelly, P.A., 1996. Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor. *J. Biol. Chem.* 271, 695–701.
- Haq, S.E.A., Clerk, A., Sugden, P.H., 1998. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by adenosine in the perfused rat heart. *FEBS Lett.* 434, 305–308.
- Hawes, B.E., Van Biesen, T., Koch, W.J., Luttrell, L.M., Lefkowitz, R.J., 1995. Distinct pathways of G_i and G_q -mediated mitogen activated protein kinase activation. *J. Biol. Chem.* 270, 17148–17153.
- Hawes, B.E., Luttrell, L.M., Van Biesen, T., Lefkowitz, R.J., 1996. Phosphatidylinositol 3-kinase is an early intermediate in the $G\beta\gamma$ -mediated mitogen-activated protein kinase signaling pathway. *J. Biol. Chem.* 271, 12133–12136.
- Herbert, J.M., Augereau, J.M., Gleye, J., Maffrand, J.P., 1990. Chelerythrine is a potent and specific inhibitor of protein kinase C. *Biochem. Biophys. Res. Commun.* 172, 993–999.
- Hill, S.J., White, T.E., Dickenson, J.M., 1994. Synergism between A_1 adenosine and histamine H_1 receptor responses in DDT₁MF-2 cells. *Drug Dev. Res.* 31, 278.

- Igishi, T., Gutkind, G.S., 1998. Tyrosine kinases of the Src family participate in signaling to MAP kinase from both G_q and G_i -coupled receptors. *Biochem. Biophys. Res. Comm.* 244, 5–10.
- Koch, W.J., Hawes, B.E., Allen, L.F., Lefkowitz, R.J., 1994. Direct evidence that G_i -coupled receptor stimulation of mitogen-activated protein kinase is mediated by $G\beta\gamma$ activation of $p21^{ras}$. *Proc. Natl. Acad. Sci. U. S. A.* 91, 12706–12710.
- Lazareno, S., Roberts, F.F., 1987. Measuring muscarinic antagonist potency using phosphoinositide breakdown in rat cortex slices. *Br. J. Pharmacol.* 92, 677P.
- Lopez-Illasaca, M., 1998. Signaling from G-protein coupled receptors to mitogen-activated protein (MAP) kinase cascades. *Biochem. Pharmacol.* 56, 269–277.
- Lowry, O.H., Rosebrough, N.J., Farr, A.C., Randall, R.J., 1951. Protein measurements with the folin phenol reagent. *J. Biol. Chem.* 193, 265–275.
- Malarkey, K., Belham, C.M., Paul, A., Graham, A., McLees, A., Scott, P.H., Plevin, R., 1995. The regulation of tyrosine kinase signalling pathways by growth factor and G-protein coupled receptors. *Biochem. J.* 309, 361–375.
- Martiny-Brown, G., Kazanietz, M.G., Mischak, H., Blumberg, P.M., Kochs, G., Hug, H., Marme, D., Schachtele, C., 1993. Selective inhibition of protein kinase C isozymes by the indolcarbazole Gö. *J. Biol. Chem.* 268, 9194–9197.
- Mochizuki, N., Ohba, Y., Kiyokawa, E., Kurata, T., Murakami, T., Ozaki, T., Kitabatake, A., Nagashima, K., Matsuda, M., 1999. Activation of the ERK/MAPK pathway by an isoform of rap1GAP associated with $G\alpha_i$. *Nature* 400, 891–894.
- Olah, M.E., Stiles, G.L., 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. *Annu. Rev. Pharmacol. Toxicol.* 35, 581–606.
- Ono, K., Han, J., 2000. The p38 signal transduction pathway: activation and function. *Cell Signalling* 12, 1–13.
- Paul, A., Wilson, S., Belham, C.M., Robinson, C.J.M., Scott, P.H., Gould, G.W., Plevin, R., 1997. Stress-activated protein kinases: activation, regulation and function. *Cell Signalling* 9, 403–410.
- Ralevic, V., Burnstock, G., 1998. Receptors for purines and pyrimidines. *Pharmacol. Rev.* 50, 413–492.
- Robinson, A.J., Dickenson, J.M., 2000. Pertussis toxin-sensitive activation of MAP kinase by the histamine H_1 receptor in DDT₁MF-2 cells. *Br. J. Pharmacol.* 129, 251P.
- Seidel, M.G., Klinger, M., Freissmuth, M., Holler, C., 1999. Activation of mitogen-activated protein kinase by the A_{2A} adenosine receptor via a rap1-dependent and via a p21ras-dependent pathway. *J. Biol. Chem.* 274, 25833–25841.
- Sexl, V., Mancusi, G., Holler, C., GloriaMaercker, E., Schutz, W., Freissmuth, M., 1997. Stimulation of the mitogen-activated protein kinase via the A_{2A} adenosine receptor in primary human endothelial cells. *J. Biol. Chem.* 272, 5792–5799.
- Sugden, P.H., Clerk, A., 1997. Regulation of the ERK subgroup of MAP kinase cascades through G protein coupled receptors. *Cell Signalling* 9, 337–351.
- Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., Kasuga, M., 1999. PI 3-kinase gamma and protein kinase C-zeta mediate Ras-independent activation of MAP kinase by a G(i) protein coupled receptor. *EMBO J.* 18, 386–395.
- Van Biesen, T., Luttrell, L.M., Hawes, B.E., Lefkowitz, R.J., 1996. Mitogenic signaling via G-protein coupled receptors. *Endocr. Rev.* 17, 698–714.
- White, T.E., Dickenson, J.M., Alexander, S.P.H., Hill, S.J., 1992. Adenosine A_1 receptor stimulation of inositol phospholipid hydrolysis and calcium mobilisation in DDT₁MF-2 cells. *Br. J. Pharmacol.* 106, 215–221.
- Widmann, C., Gibson, S., Jarpe, M.B., Johnson, G.L., 1999. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. *Physiol. Rev.* 79, 143–180.
- Yamauchi, J., Nagao, M., Kaziro, Y., Itoh, H., 1997. Activation of p38 mitogen-activated protein kinase signalling through G protein-coupled receptors. *J. Biol. Chem.* 272, 27771–27777.
- Zwartkruis, F.J.T., Bos, J.L., 1999. Ras and Rap1: two highly related small GTPases with distinct function. *Exp. Cell Res.* 253, 157–165.
- Zwick, E., Hackel, P.O., Prenzel, N., Ullrich, A., 1999. The EGF receptor as central transducer of heterologous signalling systems. *Trends Pharmacol. Sci.* 20, 408–412.